Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation
with Neurological Disorders

Rishav      Sharma; Rishabha      Malviya; Saurabh      Srivastava; Irfan      Ahmad; Safia   Obaidur   Rab; Prerna      Uniyal
Abstract

Mitochondria are an essential intracellular organelle for medication targeting and delivery since they seem to create energy and conduct many other cellular tasks, and mitochondrial dysfunctions and malfunctions lead to many illnesses. Many initiatives have been taken to detect, diagnose, and image mitochondrial abnormalities, and to transport and accumulate medicines precisely to mitochondria, all because of special mitochondrial aspects of the pathophysiology of cancer. In addition to the negative membrane potential and paradoxical mitochondrial dynamics, they include high temperatures, high levels of reactive oxygen species, high levels of glutathione, and high temperatures. Neurodegenerative diseases represent a broad spectrum of debilitating illnesses. They are linked to the loss of certain groups of neurons based on an individual's physiology or anatomy. The mitochondria in a cell are generally accepted as the authority with respect to ATP production. Disruption of this system is linked to several cellular physiological issues. The development of neurodegenerative disorders has been linked to mitochondrial malfunction, according to pathophysiological studies. There seems to be substantial evidence connecting mitochondrial dysfunction and oxidative stress to the development of neurodegenerative disorders. It has been extensively observed that mitochondrial malfunction triggers autophagy, which plays a role in neurodegenerative disorders. In addition, excitotoxicity and mitochondrial dysfunction have been linked to the development of neurodegenerative disorders. The pathophysiology of neurodegenerative illnesses has been linked to increased apoptosis and necrosis, as well as mitochondrial malfunction. A variety of synthetic and natural treatments have shown efficacy in treating neurodegenerative illnesses caused by mitochondrial failure. Neurodegenerative illnesses can be effectively treated with existing drugs that target mitochondria, although their precise formulations are poorly understood. Therefore, there is an immediate need to focus on creating drug delivery methods specifically targeted at mitochondria in the treatment and diagnosis of neurodegenerative disorders.
[1]
Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: Pathogenesis and treatment. CNS Neurosci Ther  2017; 23(1): 5-22.
 [http://dx.doi.org/10.1111/cns.12655] [PMID: 27873462]

[2]
Weng M, Xie X, Liu C, Lim KL, Zhang C, Li L. The sources of reactive oxygen species and its possible role in the pathogenesis of Parkinson’s disease. Parkinsons Dis  2018; 2018: 1-9.
 [http://dx.doi.org/10.1155/2018/9163040] [PMID: 30245802]

[3]
Chan F, Lax NZ, Davies CH, Turnbull DM, Cunningham MO. Neuronal oscillations: A physiological correlate for targeting mitochondrial dysfunction in neurodegenerative diseases? Neuropharmacology  2016; 102: 48-58.
 [http://dx.doi.org/10.1016/j.neuropharm.2015.10.033] [PMID: 26518370]

[4]
Akbar M, Essa MM, Daradkeh G, et al. Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress. Brain Res  2016; 1637: 34-55.
 [http://dx.doi.org/10.1016/j.brainres.2016.02.016] [PMID: 26883165]

[5]
van Horssen J, van Schaik P, Witte M. Inflammation and mitochondrial dysfunction: A vicious circle in neurodegenerative disorders? Neurosci Lett  2019; 710: 132931.
 [http://dx.doi.org/10.1016/j.neulet.2017.06.050] [PMID: 28668382]

[6]
Wang Z, Guo W, Kuang X, Hou S, Liu H. Nanopreparations for mitochondria targeting drug delivery system: Current strategies and future prospective. Asian J Pharmaceut Sci  2017; : 132931-508.12(6): 498-508.

[7]
Lee J. Mitochondrial drug targets in neurodegenerative diseases. Bioorg Med Chem Lett  2016; 26(3): 714-20.
 [http://dx.doi.org/10.1016/j.bmcl.2015.11.032] [PMID: 26806044]

[8]
Duchen MR. Roles of mitochondria in health and disease. Diabetes  2004; 53 (Suppl. 1): S96-S102.
 [http://dx.doi.org/10.2337/diabetes.53.2007.S96] [PMID: 14749273]

[9]
Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: Doubt no more. Biochim Biophys Acta Bioenerg  1998; 1366(1-2): 151-65.
 [http://dx.doi.org/10.1016/S0005-2728(98)00110-8]

[10]
Ricci J-E, Waterhouse N, Green DR. Mitochondrial functions during cell death, a complex (I–V) dilemma. Cell Death Differ  2003; 10(5): 488-92.
 [http://dx.doi.org/10.1038/sj.cdd.4401225] [PMID: 12728246]

[11]
Corona JC, Duchen MR. Impaired mitochondrial homeostasis and neurodegeneration: Towards new therapeutic targets? J Bioenerg Biomembr  2015; 47(1-2): 89-99.
 [http://dx.doi.org/10.1007/s10863-014-9576-6] [PMID: 25216534]

[12]
Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts  2016; 6(4): 225-48.
 [http://dx.doi.org/10.15171/bi.2016.30] [PMID: 28265539]

[13]
Laksitorini M, Prasasty VD, Kiptoo PK, Siahaan TJ. Pathways and progress in improving drug delivery through the intestinal mucosa and blood–brain barriers. Ther Deliv  2014; 5(10): 1143-63.
 [http://dx.doi.org/10.4155/tde.14.67] [PMID: 25418271]

[14]
Sanchez-Covarrubias L, Slosky L, Thompson B, Davis T, Ronaldson P. Transporters at CNS barrier sites: Obstacles or opportunities for drug delivery? Curr Pharm Des  2014; 20(10): 1422-49.
 [http://dx.doi.org/10.2174/13816128113199990463] [PMID: 23789948]

[15]
Arun S, Liu L, Donmez G. Mitochondrial biology and neurological diseases. Curr Neuropharmacol  2016; 14(2): 143-54.
 [http://dx.doi.org/10.2174/1570159X13666150703154541] [PMID: 26903445]

[16]
Liao Y, Dong Y, Cheng J. The function of the mitochondrial calcium uniporter in neurodegenerative disorders. Int J Mol Sci  2017; 18(2): 248.
 [http://dx.doi.org/10.3390/ijms18020248] [PMID: 28208618]

[17]
Hu Q, Wang G. Mitochondrial dysfunction in Parkinson’s disease. Transl Neurodegener  2016; 5(1): 14.
 [http://dx.doi.org/10.1186/s40035-016-0060-6] [PMID: 27453777]

[18]
Mukherjee A, Becerra Calixto AD, Chavez M, Delgado JP, Soto C. Mitochondrial transplant to replenish damaged mitochondria: A novel therapeutic strategy for neurodegenerative diseases? Prog Mol Biol Transl Sci  2021; 177: 49-63.
 [http://dx.doi.org/10.1016/bs.pmbts.2020.10.001] [PMID: 33453942]

[19]
Roca-Portoles A, Tait SWG. Mitochondrial quality control: From molecule to organelle. Cell Mol Life Sci  2021; 78(8): 3853-66.
 [http://dx.doi.org/10.1007/s00018-021-03775-0] [PMID: 33782711]

[20]
Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct Target Ther  2019; 4(1): 29.
 [http://dx.doi.org/10.1038/s41392-019-0063-8]

[21]
Goyal S, Chaturvedi RK. Mitochondrial protein import dysfunction in the pathogenesis of neurodegenerative diseases. Mol Neurobiol  2021; 58(4): 1418-37.
 [http://dx.doi.org/10.1007/s12035-020-02200-0] [PMID: 33180216]

[22]
Wang XL, Feng ST, Wang ZZ, Chen NH, Zhang Y. Role of mitophagy in mitochondrial quality control: Mechanisms and potential implications for neurodegenerative diseases. Pharmacol Res  2021; 165: 105433.
 [http://dx.doi.org/10.1016/j.phrs.2021.105433] [PMID: 33454337]

[23]
Hroudová J, Singh N, Fišar Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer’s disease. BioMed Res Int  2014; 2014: 1-9.
 [http://dx.doi.org/10.1155/2014/175062] [PMID: 24900954]

[24]
Ľupták M, Hroudová J. Important role of mitochondria and the effect of mood stabilizers on mitochondrial function. Physiol Res  2019; 68 (Suppl. 1): S3-S15.
 [http://dx.doi.org/10.33549/physiolres.934324] [PMID: 31755286]

[25]
Roger AJ, Muñoz-Gómez SA, Kamikawa R. The origin and diversification of mitochondria. Curr Biol  2017; 27(21): R1177-92.
 [http://dx.doi.org/10.1016/j.cub.2017.09.015] [PMID: 29112874]

[26]
Tandler B, Hoppel C, Mears J. Morphological pathways of mitochondrial division. Antioxidants  2018; 7(2): 30.
 [http://dx.doi.org/10.3390/antiox7020030] [PMID: 29462856]

[27]
Wang X, Zheng W. Ca 2+ homeostasis dysregulation in Alzheimer’s disease: A focus on plasma membrane and cell organelles. FASEB J  2019; 33(6): 6697-712.
 [http://dx.doi.org/10.1096/fj.201801751R] [PMID: 30848934]

[28]
Oxenoid K, Dong Y, Cao C, et al. Architecture of the mitochondrial calcium uniporter. Nature  2016; 533(7602): 269-73.
 [http://dx.doi.org/10.1038/nature17656] [PMID: 27135929]

[29]
Jiang Q, Yin J, Chen J, et al. Mitochondria-targeted antioxidants: A step towards disease treatment. Oxid Med Cell Longev  2020; 2020: 1-18.
 [http://dx.doi.org/10.1155/2020/8837893] [PMID: 33354280]

[30]
Cavalcante GC, Schaan AP, Cabral GF, et al. A cell’s fate: An overview of the molecular biology and genetics of apoptosis. Int J Mol Sci  2019; 20(17): 4133.
 [http://dx.doi.org/10.3390/ijms20174133] [PMID: 31450613]

[31]
Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun  2020; 11(1): 102.
 [http://dx.doi.org/10.1038/s41467-019-13668-3] [PMID: 31900386]

[32]
West AP. Mitochondrial dysfunction as a trigger of innate immune responses and inflammation. Toxicology  2017; 391: 54-63.
 [http://dx.doi.org/10.1016/j.tox.2017.07.016] [PMID: 28765055]

[33]
Konat GW, Wiggins RC. Effect of reactive oxygen species on myelin membrane proteins. J Neurochem  1985; 45(4): 1113-8.
 [http://dx.doi.org/10.1111/j.1471-4159.1985.tb05530.x] [PMID: 4031880]

[34]
Wang W, Zhang F, Li L, et al. MFN2 couples glutamate excitotoxicity and mitochondrial dysfunction in motor neurons. J Biol Chem  2015; 290(1): 168-82.
 [http://dx.doi.org/10.1074/jbc.M114.617167] [PMID: 25416777]

[35]
Souto EB, Severino P, Basso R, Santana MHA. Encapsulation of antioxidants in gastrointestinal-resistant nanoparticulate carriers. Methods Mol Biol  2013; 1028: 37-46.
 [http://dx.doi.org/10.1007/978-1-62703-475-3_3]

[36]
Brieger K, Schiavone S, Miller J Jr, Krause KH. Reactive oxygen species: From health to disease. Swiss Med Wkly  2012; 142: w13659.
 [http://dx.doi.org/10.4414/smw.2012.13659] [PMID: 22903797]

[37]
Morais VA, De Strooper B. Mitochondria dysfunction and neurodegenerative disorders: Cause or consequence. J Alzheimers Dis  2010; 20(s2) (Suppl. 2): S255-63.
 [http://dx.doi.org/10.3233/JAD-2010-100345] [PMID: 20463408]

[38]
Kumar A, Singh A. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions. Front Pharmacol  2015; 6: 206.
 [http://dx.doi.org/10.3389/fphar.2015.00206] [PMID: 26441662]

[39]
Pathak RK, Kolishetti N, Dhar S. Targeted nanoparticles in mitochondrial medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2015; 7(3): 315-29.
 [http://dx.doi.org/10.1002/wnan.1305] [PMID: 25348382]

[40]
Tonda-Turo C, Origlia N, Mattu C, Accorroni A, Chiono V. Current limitations in the treatment of Parkinson’s and Alzheimer’s diseases: State-of-the-art and future perspective of polymeric carriers. Curr Med Chem  2019; 25(41): 5755-71.
 [http://dx.doi.org/10.2174/0929867325666180221125759] [PMID: 29473493]

[41]
Pezzini I, Mattoli V, Ciofani G. Mitochondria and neurodegenerative diseases: The promising role of nanotechnology in targeted drug delivery. Expert Opin Drug Deliv  2017; 14(4): 513-23.
 [http://dx.doi.org/10.1080/17425247.2016.1218461] [PMID: 27467010]

[42]
Ramanathan S, Archunan G, Sivakumar M, et al. Theranostic applications of nanoparticles in neurodegenerative disorders. Int J Nanomedicine  2018; 13: 5561-76.
 [http://dx.doi.org/10.2147/IJN.S149022] [PMID: 30271147]

[43]
Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature  2011; 469(7329): 221-5.
 [http://dx.doi.org/10.1038/nature09663] [PMID: 21124315]

[44]
Abcouwer SF, Shanmugam S, Gomez PF, et al. Effect of IL-1β on survival and energy metabolism of R28 and RGC-5 retinal neurons. Invest Ophthalmol Vis Sci  2008; 49(12): 5581-92.
 [http://dx.doi.org/10.1167/iovs.07-1032] [PMID: 19037001]

[45]
Chen GY, Nuñez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol  2010; 10(12): 826-37.
 [http://dx.doi.org/10.1038/nri2873] [PMID: 21088683]

[46]
Tait SWG, Green DR. Mitochondria and cell signalling. J Cell Sci  2012; 125(4): 807-15.
 [http://dx.doi.org/10.1242/jcs.099234] [PMID: 22448037]

[47]
West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol  2011; 11(6): 389-402.
 [http://dx.doi.org/10.1038/nri2975] [PMID: 21597473]

[48]
Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature  2010; 464(7285): 104-7.
 [http://dx.doi.org/10.1038/nature08780] [PMID: 20203610]

[49]
Fang C, Wei X, Wei Y. Mitochondrial DNA in the regulation of innate immune responses. Protein Cell  2016; 7(1): 11-6.
 [http://dx.doi.org/10.1007/s13238-015-0222-9] [PMID: 26498951]

[50]
Nakahira K, Haspel JA, Rathinam VAK, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol  2011; 12(3): 222-30.
 [http://dx.doi.org/10.1038/ni.1980] [PMID: 21151103]

[51]
Oka T, Hikoso S, Yamaguchi O, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature  2012; 485(7397): 251-5.
 [http://dx.doi.org/10.1038/nature10992] [PMID: 22535248]

[52]
Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J  2004; 18(2): 1-17.
 [http://dx.doi.org/10.1096/fj.03-0670fje] [PMID: 14688201]

[53]
Walko TD III, Bola RA, Hong JD, et al. Cerebrospinal fluid mitochondrial DNA: A novel DAMP in pediatric traumatic brain injury. Shock  2014; 41(6): 499-503.
 [http://dx.doi.org/10.1097/SHK.0000000000000160] [PMID: 24667615]

[54]
Varhaug KN, Vedeler CA, Myhr KM, Aarseth JH, Tzoulis C, Bindoff LA. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion  2017; 34: 32-5.
 [http://dx.doi.org/10.1016/j.mito.2016.12.003] [PMID: 28017684]

[55]
Raoof M, Zhang Q, Itagaki K, Hauser CJ. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J Trauma  2010; 68(6): 1328-34.
 [http://dx.doi.org/10.1097/TA.0b013e3181dcd28d] [PMID: 20539176]

[56]
Cui YH, Le Y, Gong W, et al. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J Immunol  2002; 168(1): 434-42.
 [http://dx.doi.org/10.4049/jimmunol.168.1.434] [PMID: 11751990]

[57]
Durazo SA, Kompella UB. Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion  2012; 12(2): 190-201.
 [http://dx.doi.org/10.1016/j.mito.2011.11.001] [PMID: 22138492]

[58]
Chidambaram SB, Bhat A, Ray B, et al. Cocoa beans improve mitochondrial biogenesis via PPARγ/PGC1α dependent signalling pathway in MPP + intoxicated human neuroblastoma cells (SH-SY5Y). Nutr Neurosci  2020; 23(6): 471-80.
 [http://dx.doi.org/10.1080/1028415X.2018.1521088] [PMID: 30207204]

[59]
Puspita L, Chung SY, Shim J. Oxidative stress and cellular pathologies in Parkinson’s disease. Mol Brain  2017; 10(1): 53.
 [http://dx.doi.org/10.1186/s13041-017-0340-9] [PMID: 29183391]

[60]
Essa MM, Moghadas M, Ba-Omar T, et al. Protective effects of antioxidants in Huntington’s disease: An extensive review. Neurotox Res  2019; 35(3): 739-74.
 [http://dx.doi.org/10.1007/s12640-018-9989-9] [PMID: 30632085]

[61]
Ranju V, Sathiya S, Kalaivani P, Priya RJ, Saravana Babu C. Memantine exerts functional recovery by improving BDNF and GDNF expression in 3-nitropropionic acid intoxicated mice. Neurosci Lett  2015; 586: 1-7.
 [http://dx.doi.org/10.1016/j.neulet.2014.11.036] [PMID: 25475686]

[62]
Joshi AU, Mochly-Rosen D. Mortal engines: Mitochondrial bioenergetics and dysfunction in neurodegenerative diseases. Pharmacol Res  2018; 138: 2-15.
 [http://dx.doi.org/10.1016/j.phrs.2018.08.010] [PMID: 30144530]

[63]
Ettle B, Schlachetzki JCM, Winkler J. Oligodendroglia and myelin in neurodegenerative diseases: More than just bystanders? Mol Neurobiol  2016; 53(5): 3046-62.
 [http://dx.doi.org/10.1007/s12035-015-9205-3] [PMID: 25966971]

[64]
Carvalho L, Goodyear P. The architecture of productive learning networks.  (1st ed..). New York: Routledge 2014; p. 312.
 [http://dx.doi.org/10.4324/9780203591093]

[65]
McConnell HL, Kersch CN, Woltjer RL, Neuwelt EA. The translational significance of the neurovascular unit. J Biol Chem  2017; 292(3): 762-70.
 [http://dx.doi.org/10.1074/jbc.R116.760215] [PMID: 27920202]

[66]
Diogo CV, Yambire KF, Fernández Mosquera L, Branco F T, Raimundo N. Mitochondrial adventures at the organelle society. Biochem Biophys Res Commun  2018; 500(1): 87-93.
 [http://dx.doi.org/10.1016/j.bbrc.2017.04.124] [PMID: 28456629]

[67]
Andreux PA, Houtkooper RH, Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov  2013; 12(6): 465-83.
 [http://dx.doi.org/10.1038/nrd4023] [PMID: 23666487]

[68]
Murphy MP, Hartley RC. Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov  2018; 17(12): 865-86.
 [http://dx.doi.org/10.1038/nrd.2018.174] [PMID: 30393373]

[69]
Saka R, Sathe P, Khan W. Brain local delivery strategy.Brain Targeted Drug Delivery System.  Amsterdam: Elsevier 2019; pp. 241-86.
 [http://dx.doi.org/10.1016/B978-0-12-814001-7.00011-1]

[70]
Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. AAPS J  2015; 17(6): 1327-40.
 [http://dx.doi.org/10.1208/s12248-015-9814-9] [PMID: 26276218]

[71]
Torres-Ortega PV, Saludas L, Hanafy AS, Garbayo E, Blanco-Prieto MJ. Micro- and nanotechnology approaches to improve Parkinson’s disease therapy. J Control Release  2019; 295: 201-13.
 [http://dx.doi.org/10.1016/j.jconrel.2018.12.036] [PMID: 30579984]

[72]
Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx  2005; 2(1): 3-14.
 [http://dx.doi.org/10.1602/neurorx.2.1.3] [PMID: 15717053]

[73]
de Jong WH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine  2008; 3(2): 133-49.
 [http://dx.doi.org/10.2147/IJN.S596] [PMID: 18686775]

[74]
Goyanes A, Det-Amornrat U, Wang J, Basit AW, Gaisford S. 3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems. J Control Release  2016; 234: 41-8.
 [http://dx.doi.org/10.1016/j.jconrel.2016.05.034] [PMID: 27189134]

[75]
Soni S, Ruhela RK, Medhi B. Nanomedicine in central nervous system (CNS) disorders: A present and future prospective. Adv Pharm Bull  2016; 6(3): 319-35.
 [http://dx.doi.org/10.15171/apb.2016.044] [PMID: 27766216]

[76]
Pelaz B, Alexiou C, Alvarez-Puebla RA, et al. Diverse applications of nanomedicine. ACS Nano  2017; 11(3): 2313-81.
 [http://dx.doi.org/10.1021/acsnano.6b06040] [PMID: 28290206]

[77]
Clementino A, Batger M, Garrastazu G, et al. The nasal delivery of nanoencapsulated statins – an approach for brain delivery. Int J Nanomedicine  2016; 11: 6575-90.
 [http://dx.doi.org/10.2147/IJN.S119033] [PMID: 27994459]

[78]
Alex AT, Joseph A, Shavi G, Rao JV, Udupa N. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv  2016; 23(7): 2144-53.
 [http://dx.doi.org/10.3109/10717544.2014.948643] [PMID: 25544603]

[79]
Dowding JM, Song W, Bossy K, et al. Cerium oxide nanoparticles protect against Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ  2014; 21(10): 1622-32.
 [http://dx.doi.org/10.1038/cdd.2014.72] [PMID: 24902900]

[80]
Guerzoni LPB, Nicolas V, Angelova A. in vitro, modulation of TrkB receptor signaling upon sequential delivery of curcumin-DHA loaded carriers towards promoting neuronal survival. Pharm Res  2017; 34(2): 492-505.
 [http://dx.doi.org/10.1007/s11095-016-2080-4] [PMID: 27995523]

[81]
Kovacic P, Somanathan R. Biomechanisms of nanoparticles (toxicants, antioxidants and therapeutics): Electron transfer and reactive oxygen species. J Nanosci Nanotechnol  2010; 10(12): 7919-30.
 [http://dx.doi.org/10.1166/jnn.2010.3028] [PMID: 21121279]

[82]
Bae Y, Jung MK, Lee S, et al. Dequalinium-based functional nanosomes show increased mitochondria targeting and anticancer effect. Eur J Pharm Biopharm  2018; 124: 104-15.
 [http://dx.doi.org/10.1016/j.ejpb.2017.12.013] [PMID: 29305141]

[83]
Wongrakpanich A, Geary SM, Joiner MA, Anderson ME, Salem AK. Mitochondria-targeting particles. Nanomedicine (Lond)  2014; 9(16): 2531-43.
 [http://dx.doi.org/10.2217/nnm.14.161] [PMID: 25490424]

[84]
Zielonka J, Joseph J, Sikora A, et al. Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev  2017; 117(15): 10043-120.
 [http://dx.doi.org/10.1021/acs.chemrev.7b00042] [PMID: 28654243]

[85]
Battogtokh G, Choi YS, Kang DS, et al. Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: Current strategies and future perspectives. Acta Pharm Sin B  2018; 8(6): 862-80.
 [http://dx.doi.org/10.1016/j.apsb.2018.05.006] [PMID: 30505656]

[86]
Battogtokh G, Cho YY, Lee JY, Lee HS, Kang HC. Mitochondrial-targeting anticancer agent conjugates and nanocarrier systems for cancer treatment. Front Pharmacol  2018; 9: 922.
 [http://dx.doi.org/10.3389/fphar.2018.00922] [PMID: 30174604]

[87]
Calió ML, Henriques E, Siena A, Bertoncini CRA, Gil-Mohapel J, Rosenstock TR. Mitochondrial dysfunction, neurogenesis, and epigenetics: Putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front Neurosci  2020; 14: 679.
 [http://dx.doi.org/10.3389/fnins.2020.00679] [PMID: 32760239]

[88]
Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Mitochondrial dysfunction and mitophagy in Parkinson’s disease: From mechanism to therapy. Trends Biochem Sci  2021; 46(4): 329-43.
 [http://dx.doi.org/10.1016/j.tibs.2020.11.007] [PMID: 33323315]

[89]
Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances. Mol Neurodegener  2020; 15(1): 30.
 [http://dx.doi.org/10.1186/s13024-020-00376-6] [PMID: 32471464]

[90]
Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med  2014; 20(3): 179-87.
 [http://dx.doi.org/10.1016/j.molmed.2013.11.007] [PMID: 24369898]

[91]
Muyderman H, Chen T. Mitochondrial dysfunction in amyotrophic lateral sclerosis – a valid pharmacological target? Br J Pharmacol  2014; 171(8): 2191-205.
 [http://dx.doi.org/10.1111/bph.12476] [PMID: 24148000]

[92]
Folbergrová J, Kunz WS. Mitochondrial dysfunction in epilepsy. Mitochondrion  2012; 12(1): 35-40.
 [http://dx.doi.org/10.1016/j.mito.2011.04.004] [PMID: 21530687]

[93]
Sulaiman SA, Rani ZM, Radin FZM, Murad NAA. Advancement in the diagnosis of mitochondrial diseases. J Transl Gene Gen  2020; 4(3): 159-87.
 [http://dx.doi.org/10.20517/jtgg.2020.27]

[94]
Jurcau A. Insights into the pathogenesis of neurodegenerative diseases: Focus on mitochondrial dysfunction and oxidative stress. Int J Mol Sci  2021; 22(21): 11847.
 [http://dx.doi.org/10.3390/ijms222111847] [PMID: 34769277]

[95]
Larosa V, Remacle C. Insights into the respiratory chain and oxidative stress. Biosci Rep  2018; 38(5): BSR20171492.
 [http://dx.doi.org/10.1042/BSR20171492] [PMID: 30201689]

[96]
Guo C, Sun L, Chen X, Zhang D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res  2013; 8(21): 2003-14.
 [PMID: 25206509]

[97]
Selvaraji S, Poh L, Natarajan V, Mallilankaraman K, Arumugam TV. Negative conditioning of mitochondrial dysfunction in age-related neurodegenerative diseases. Cond Med  2019; 2(1): 30-9.
 [PMID: 31058265]

[98]
Alzheimer’s Association. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement  2019; 15(3): 321-87.
 [http://dx.doi.org/10.1016/j.jalz.2019.01.010]

[99]
Mebane-Sims I. Alzheimer’s Association, 2018 Alzheimer’s disease facts and figures. Alzheimers Dement  2018; 14(3): 367-429.
 [http://dx.doi.org/10.1016/j.jalz.2018.02.001]

[100]
Waseem R, Shamsi A, Mohammad T, et al. Multispectroscopic and molecular docking insight into elucidating the interaction of irisin with Rivastigmine tartrate: A combinational therapy approach to fight Alzheimer’s disease. ACS Omega  2021; 6(11): 7910-21.
 [http://dx.doi.org/10.1021/acsomega.1c00517] [PMID: 33778302]

[101]
Waseem R, Shamsi A, Mohammad T, et al. FNDC5/Irisin: Physiology and pathophysiology. Molecules  2022; 27(3): 1118.
 [http://dx.doi.org/10.3390/molecules27031118] [PMID: 35164383]

[102]
Förstl H, Kurz A. Clinical features of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci  1999; 249(6): 288-90.
 [http://dx.doi.org/10.1007/s004060050101] [PMID: 10653284]

[103]
Waseem R, Anwar S, Khan S, et al. MAP/Microtubule affinity regulating kinase 4 inhibitory potential of Irisin: A new therapeutic strategy to combat cancer and alzheimer’s disease. Int J Mol Sci  2021; 22(20): 10986.
 [http://dx.doi.org/10.3390/ijms222010986] [PMID: 34681645]

[104]
Silva DF, Selfridge JE, Lu J, e L, Cardoso SM, Swerdlow RH. Mitochondrial abnormalities in Alzheimer’s disease: Possible targets for therapeutic intervention. Adv Pharmacol  2012; 64: 83-126.
 [http://dx.doi.org/10.1016/B978-0-12-394816-8.00003-9] [PMID: 22840745]

[105]
Blagov AV, Grechko AV, Nikiforov NG, Borisov EE, Sadykhov NK, Orekhov AN. Role of impaired mitochondrial dynamics processes in the pathogenesis of Alzheimer’s disease. Int J Mol Sci  2022; 23(13): 6954.
 [http://dx.doi.org/10.3390/ijms23136954] [PMID: 35805958]

[106]
Flannery PJ, Trushina E. Mitochondrial dysfunction in Alzheimer’s disease and progress in mitochondria-targeted therapeutics. Curr Behav Neurosci Rep  2019; 6(3): 88-102.
 [http://dx.doi.org/10.1007/s40473-019-00179-0]

[107]
Wang X, Wang W, Li L, Perry G, Lee H, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis  2014; 1842(8): 1240-7.
 [http://dx.doi.org/10.1016/j.bbadis.2013.10.015] [PMID: 24189435]

[108]
Cenini G, Voos W. Mitochondria as potential targets in Alzheimer disease therapy: An update. Front Pharmacol  2019; 10: 902.
 [http://dx.doi.org/10.3389/fphar.2019.00902] [PMID: 31507410]

[109]
Agrawal I, Jha S. Mitochondrial dysfunction and Alzheimer’s disease: Role of microglia. Front Aging Neurosci  2020; 12: 252.
 [http://dx.doi.org/10.3389/fnagi.2020.00252] [PMID: 32973488]

[110]
Feeney CJ, Frantseva MV, Carlen PL, et al. Vulnerability of glial cells to hydrogen peroxide in cultured hippocampal slices. Brain Res  2008; 1198: 1-15.
 [http://dx.doi.org/10.1016/j.brainres.2007.12.049] [PMID: 18261717]

[111]
Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. cellular and molecular basis of neurodegeneration in Parkinson’s disease. Front Aging Neurosci  2018; 10: 109.
 [http://dx.doi.org/10.3389/fnagi.2018.00109] [PMID: 29719505]

[112]
Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson’s disease: From James Parkinson to the concept of prodromal disease. Front Neurol  2018; 9: 156.
 [http://dx.doi.org/10.3389/fneur.2018.00156] [PMID: 29628907]

[113]
Dickson DW. Parkinson’s disease and parkinsonism: Neuropathology. Cold Spring Harb Perspect Med  2012; 2(8): a009258.
 [http://dx.doi.org/10.1101/cshperspect.a009258] [PMID: 22908195]

[114]
Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell  2019; 18(6): e13031.
 [http://dx.doi.org/10.1111/acel.13031] [PMID: 31432604]

[115]
Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet  2006; 38(5): 515-7.
 [http://dx.doi.org/10.1038/ng1769] [PMID: 16604074]

[116]
Gu G, Reyes PF, Golden GT, et al. Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol  2002; 61(7): 634-9.
 [http://dx.doi.org/10.1093/jnen/61.7.634] [PMID: 12125742]

[117]
Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: Clinical and molecular genetic study. Lancet  2004; 364(9437): 875-82.
 [http://dx.doi.org/10.1016/S0140-6736(04)16983-3] [PMID: 15351195]

[118]
Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease. Pharm Res  2006; 23(7): 1417-50.
 [http://dx.doi.org/10.1007/s11095-006-0284-8] [PMID: 16779701]

[119]
Gruber J, Fong S, Chen CB, et al. Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol Adv  2013; 31(5): 563-92.
 [http://dx.doi.org/10.1016/j.biotechadv.2012.09.005] [PMID: 23022622]

[120]
Lü JM, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn  2009; 9(4): 325-41.
 [http://dx.doi.org/10.1586/erm.09.15] [PMID: 19435455]

[121]
Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci USA  2012; 109(40): 16288-93.
 [http://dx.doi.org/10.1073/pnas.1210096109] [PMID: 22991470]

[122]
Tiwari SK, Agarwal S, Seth B, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano  2014; 8(1): 76-103.
 [http://dx.doi.org/10.1021/nn405077y] [PMID: 24467380]

[123]
Zhang E, Zhang C, Su Y, Cheng T, Shi C. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov Today  2011; 16(3-4): 140-6.
 [http://dx.doi.org/10.1016/j.drudis.2010.12.006] [PMID: 21182981]

[124]
Weissig V, Torchilin VP. Towards mitochondrial gene therapy: DQAsomes as a strategy. J Drug Target  2001; 9(1): 1-13.
 [http://dx.doi.org/10.3109/10611860108995628] [PMID: 11378519]

[125]
D’Souza GGM, Boddapati SV, Weissig V. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion  2005; 5(5): 352-8.
 [http://dx.doi.org/10.1016/j.mito.2005.07.001] [PMID: 16154389]

[126]
Kumar P, Kalonia H, Kumar A. Sesamol attenuate 3-nitropropionic acid-induced Huntington-like behavioral, biochemical, and cellular alterations in rats. J Asian Nat Prod Res  2009; 11(5): 439-50.
 [http://dx.doi.org/10.1080/10286020902862194] [PMID: 19504387]

[127]
Hao S, Ji J, Zhao H, et al. Mitochondrion-targeted peptide SS-31 inhibited oxidized low-density lipoproteins-induced foam cell formation through both ROS scavenging and inhibition of cholesterol influx in RAW264. 7 cells. Molecules  2015; 20(12): 21287-97.
 [http://dx.doi.org/10.3390/molecules201219764] [PMID: 26633327]

[128]
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature  2006; 443(7113): 787-95.
 [http://dx.doi.org/10.1038/nature05292] [PMID: 17051205]

[129]
Kasote DM, Hegde MV, Katyare SS. Mitochondrial dysfunction in psychiatric and neurological diseases: Cause(s), consequence(s), and implications of antioxidant therapy. Biofactors  2013; 39(4): 392-406.
 [http://dx.doi.org/10.1002/biof.1093] [PMID: 23460132]

[130]
Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life  2008; 60(9): 575-90.
 [http://dx.doi.org/10.1002/iub.91] [PMID: 18478527]

[131]
Ferreiro E, Baldeiras I, Ferreira IL, et al. Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer’s disease: From pathogenesis to biomarkers. Int J Cell Biol  2012; 2012: 1-23.
 [http://dx.doi.org/10.1155/2012/735206] [PMID: 22701485]

[132]
Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol  2003; 161(1): 41-54.
 [http://dx.doi.org/10.1083/jcb.200207030] [PMID: 12695498]

[133]
Giasson BI, Ischiropoulos H, Lee VMY, Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases1,2 11Guest Editors: Mark A. Smith and George Perry 22This article is part of a series of reviews on “Causes and Consequences of Oxidative Stress in Alzheimer’s Disease.” The full list of papers may be found on the homepage of the journal. Free Radic Biol Med  2002; 32(12): 1264-75.
 [http://dx.doi.org/10.1016/S0891-5849(02)00804-3] [PMID: 12057764]

[134]
Andersen JK. Oxidative stress in neurodegeneration: Cause or consequence? Nat Med  2004; 10(S7) (Suppl.): S18-25.
 [http://dx.doi.org/10.1038/nrn1434] [PMID: 15298006]

[135]
Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science  2004; 304(5669): 448-52.
 [http://dx.doi.org/10.1126/science.1091230] [PMID: 15087549]

[136]
Dumont M, Ho DJ, Calingasan NY, Xu H, Gibson G, Beal MF. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radic Biol Med  2009; 47(7): 1019-27.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2009.07.008] [PMID: 19596066]

[137]
Shi Q, Xu H, Yu H, et al. Inactivation and reactivation of the mitochondrial α-ketoglutarate dehydrogenase complex. J Biol Chem  2011; 286(20): 17640-8.
 [http://dx.doi.org/10.1074/jbc.M110.203018] [PMID: 21454586]

[138]
Coskun PE, Beal MF, Wallace DC. Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA  2004; 101(29): 10726-31.
 [http://dx.doi.org/10.1073/pnas.0403649101] [PMID: 15247418]

[139]
Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer’s disease: Implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol  2006; 2006(3): 1-13.
 [http://dx.doi.org/10.1155/JBB/2006/31372] [PMID: 17047303]

[140]
Tranah GJ, Nalls MA, Katzman SM, et al. Mitochondrial DNA sequence variation associated with dementia and cognitive function in the elderly. J Alzheimers Dis  2012; 32(2): 357-72.
 [http://dx.doi.org/10.3233/JAD-2012-120466] [PMID: 22785396]

[141]
Giasson BI, Lee VMY. A new link between pesticides and Parkinson’s disease. Nat Neurosci  2000; 3(12): 1227-8.
 [http://dx.doi.org/10.1038/81737] [PMID: 11100135]

[142]
Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson’s disease–correlations with inflammatory cytokines in serum. PLoS One  2012; 7(10): e47387.
 [http://dx.doi.org/10.1371/journal.pone.0047387]

[143]
Abeliovich A. Mitochondrial damage control. Nature  2010; 463(7282): 744-5.
 [http://dx.doi.org/10.1038/463744a] [PMID: 20148026]

[144]
Matsui H, Gavinio R, Asano T, et al. PINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates. Hum Mol Genet  2013; 22(12): 2423-34.
 [http://dx.doi.org/10.1093/hmg/ddt095] [PMID: 23449626]

[145]
Momb J, Lewandowski JP, Bryant JD, et al. Deletion of Mthfd1l causes embryonic lethality and neural tube and craniofacial defects in mice. Proc Natl Acad Sci USA  2013; 110(2): 549-54.
 [http://dx.doi.org/10.1073/pnas.1211199110] [PMID: 23267094]

[146]
Alleyne T, Mohan N, Adogwa A. Elevated ferric, calcium and magnesium ions in the brain induce protein aggregation in brain mitochondria. West Indian Med J  2012; 61(2): 122-7.
 [PMID: 23155955]

[147]
Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson’s and Huntington’s diseases. Mol Cell Neurosci  2013; 55: 101-14.
 [http://dx.doi.org/10.1016/j.mcn.2012.11.011] [PMID: 23220289]

[148]
Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J. Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab  2013; 17(1): 132-40.
 [http://dx.doi.org/10.1016/j.cmet.2012.12.005] [PMID: 23312288]

[149]
Siddiqui A, Rivera-Sánchez S, Castro MR, et al. Mitochondrial DNA damage Is associated with reduced mitochondrial bioenergetics in Huntington’s disease. Free Radic Biol Med  2012; 53(7): 1478-88.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2012.06.008] [PMID: 22709585]

[150]
Marobbio CMT, Pisano I, Porcelli V, Lasorsa FM, Palmieri L. Rapamycin reduces oxidative stress in frataxin-deficient yeast cells. Mitochondrion  2012; 12(1): 156-61.
 [http://dx.doi.org/10.1016/j.mito.2011.07.001] [PMID: 21782979]

[151]
Santos R, Lefevre S, Sliwa D, Seguin A, Camadro JM, Lesuisse E. Friedreich ataxia: Molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal  2010; 13(5): 651-90.
 [http://dx.doi.org/10.1089/ars.2009.3015] [PMID: 20156111]

[152]
Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, Orekhov AN. The role of mitochondrial dysfunction in cardiovascular disease: A brief review. Ann Med  2018; 50(2): 121-7.
 [http://dx.doi.org/10.1080/07853890.2017.1417631] [PMID: 29237304]

[153]
Esteves AR, Arduíno DM, Swerdlow RH, Oliveira CR, Cardoso SM. Dysfunctional mitochondria uphold calpain activation: Contribution to Parkinson’s disease pathology. Neurobiol Dis  2010; 37(3): 723-30.
 [http://dx.doi.org/10.1016/j.nbd.2009.12.011] [PMID: 20034566]

[154]
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. J Cell Physiol  2019; 234(6): 8152-61.
 [http://dx.doi.org/10.1002/jcp.27603] [PMID: 30317615]

[155]
Yang JL, Mukda S, Chen SD. Diverse roles of mitochondria in ischemic stroke. Redox Biol  2018; 16: 263-75.
 [http://dx.doi.org/10.1016/j.redox.2018.03.002] [PMID: 29549824]

[156]
Gao J, Wang L, Liu J, Xie F, Su B, Wang X. Abnormalities of mitochondrial dynamics in neurodegenerative diseases. Antioxidants  2017; 6(2): 25.
 [http://dx.doi.org/10.3390/antiox6020025] [PMID: 28379197]

[157]
Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders — A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis  2017; 1863(5): 1066-77.
 [http://dx.doi.org/10.1016/j.bbadis.2016.11.010] [PMID: 27836629]
Cite As
Current Drug Targets

Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders

Abstract
